
PreDxion Bio
PreDxion Bio is a YC Summer 2017 (S17) company. Based in South San Francisco, CA, USA. Team of 6.
About PreDxion Bio
Summary
PreDxion Bio builds a rapid, saliva-based antigen detection platform for SARS-CoV-2 and other biomarkers, targeting public health officials, policymakers, and critical-care clinicians. Its core sensor technology, spun out of the University of Michigan, uses semiconductor fabrication processes to enable high-volume diagnostic testing and near real-time cytokine monitoring in critically ill patients. The platform replaces slower laboratory assays for immune-response tracking, including detection of cytokine release syndrome in CAR-T therapy patients.
Go-to-market
PreDxion Bio sells to pharmaceutical partners and healthcare institutions, engaging through research collaborations and a FDA Breakthrough Device designation that supports clinical adoption in critical care and drug development settings.
From the Y Combinator listing
Rapid, scalable diagnostic for SARS-CoV-2 and beyond
PreDxion Bio is working on a rapid saliva-based antigen test for the detection of SARS-CoV-2 S-protein in asymptomatic and presymptomatic patients. Our technology is uniquely capable of being scaled to 10's of millions of tests of days using semiconductor fab processes, a scale of testing necessary to better inform public health officials and policymakers and enable contact tracing at scale. PreDxion Bio's origins are in critical care: our original technology is a rapid, near real-time cytokine and biomarker detection platform to monitor the immune response of critically-ill patients. This technology leverages a novel sensor platform we spun out of the University of Michigan. PreDxion Bio has received FDA Breakthrough Device designation and partnered with top pharmcos to monitor the immune response following CAR-T therapy and predict the development of cytokine release syndrome and neurological AEs, and for use in guiding precision medicine approaches in critical care.
Facts
- Healthcare / Healthcare -> Diagnostics
- South San Francisco, CA, USA
- 6
- Inactive
- Early
Founders (2)
- Timothy Cornell
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works